A5033427647- Radiopharmaceutical Chemistry and Applications
- Multiple Myeloma Research and Treatments
- Chemical Synthesis and Analysis
- Prostate Cancer Treatment and Research
- Mass Spectrometry Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Bladder and Urothelial Cancer Treatments
- Medical Imaging and Pathology Studies
- Medical Imaging Techniques and Applications
- Radiation Therapy and Dosimetry
- Nuclear Physics and Applications
- Peptidase Inhibition and Analysis
University of California, San Francisco
2023-2024
UCSF Helen Diller Family Comprehensive Cancer Center
2023
Target (United States)
2021
Radiopharmaceutical therapy is changing the standard of care in prostate cancer and other malignancies. We previously reported high CD46 expression developed an antibody-drug conjugate immunoPET agent based on YS5 antibody, which targets a tumor-selective epitope. Here, we present preparation, preclinical efficacy, toxicity evaluation [225Ac]DOTA-YS5, radioimmunotherapy antibody.
Abstract Purpose: Multiple myeloma is a plasma cell malignancy with an unmet clinical need for improved imaging methods and therapeutics. Recently, we identified CD46 as overexpressed therapeutic target in multiple developed the antibody YS5, which targets cancer-specific epitope on this protein. We further CD46-targeting PET probe [89Zr]Zr-DFO-YS5 [225Ac]Ac-DOTA-YS5 radiopharmaceutical therapy of prostate cancer. These prior studies suggested feasibility antigen theranostic myeloma. Herein,...
<p>Table S21: [18F]-FDG %IA/g in the ANBL6 subcutaneous xenograft models.</p>
<p>Table S21: [18F]-FDG %IA/g in the ANBL6 subcutaneous xenograft models.</p>
<p>Table S16: [89Zr]Zr-DFO-IgG %IA/Organ in the ANBL6 subcutaneous xenograft models.</p>
<p>Table S1: Biodistribution analysis %IA/g of [89Zr]Zr-DFO-YS5 in subcutaneous MM.1S tumor model.</p>
<p>Table S7: Biodistribution analysis % IA/g of [89Zr]Zr-DFO-YS5 in subcutaneous MM.1S CD46 (-/-) tumor model.</p>
<p>Table S13: [89Zr]Zr-DFO-YS5 %IA/g in the ANBL6 subcutaneous xenograft models.</p>
<p>Table S29: [89Zr]Zr-DFO-YS5 %IA/g in the RPMI8266 systemic tumor model.</p>
<p>Figure S8: Bioluminescence Images of NSG mouse showed an increase in tumor burden gradually injected with different doses [225Ac]Ac-DOTA-YS5 from each group and saline group.</p>
<p>Table S20: [18F]-FDG %IA/Organ in the RPMI8226 subcutaneous xenograft models.</p>
<p>Figure S11: %ID/Tumor of [89Zr]Zr-DFO-YS5 in ANBL6 subcutaneous model is higher than RPMI8226 and MM.1S.</p>
<p>Figure S6: [89Zr]Zr-DFO-IgG PET imaging in the MM.1S systemic model demonstrates high nonspecific uptake bone marrow.</p>
<p>Table S8: %IA/Organ of [89Zr]Zr-DFO-YS5 in subcutaneous MM.1S CD46 (-/-) tumor model.</p>
<p>Table S18: [18F]-FDG %IA/Organ in the MM.1S subcutaneous xenograft model.</p>
<div>AbstractPurpose:<p>Multiple myeloma is a plasma cell malignancy with an unmet clinical need for improved imaging methods and therapeutics. Recently, we identified CD46 as overexpressed therapeutic target in multiple developed the antibody YS5, which targets cancer-specific epitope on this protein. We further CD46-targeting PET probe [<sup>89</sup>Zr]Zr-DFO-YS5 [<sup>225</sup>Ac]Ac-DOTA-YS5 radiopharmaceutical therapy of prostate cancer. These prior...
<p>Table S17: [18F]-FDG %IA/g in the MM.1S subcutaneous xenograft model.</p>
<p>Figure S7: [89Zr]Zr-DFO-IgG PET imaging in the healthy nude mice and NSG demonstrates significantly different uptake bone marrow.</p>
<p>Table S10: [89Zr]Zr-DFO-YS5 % IA/Organ in the RPMI8226 subcutaneous xenograft models.</p>
<p>Table S2: %IA/Organ of [89Zr]Zr-DFO-YS5 in subcutaneous MM.1S tumor model.</p>
<p>Table S31: [18F]-FDG %IA/g in the RPMI8226 systemic tumor model.</p>
<p>Table S22: [18F]-FDG %IA/Organ in the ANBL6 subcutaneous xenograft models.</p>
<p>Table S11: [89Zr]Zr-DFO-IgG %IA/g in the RPMI8226 subcutaneous xenograft models.</p>
<p>Table S27: [18F]-FDG %IA/g biodistribution in the MM.1S systemic tumor model.</p>
<p>Table S28: [18F]-FDG %IA/Organ in the MM.1S systemic tumor model.</p>